XOMA (NASDAQ:XOMA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a report issued on Wednesday morning, Benzinga reports. They currently have a $74.00 target price on the biotechnology company’s stock.

Separately, SVB Leerink initiated coverage on XOMA in a research report on Monday, April 29th. They set an outperform rating and a $40.00 price target on the stock.

XOMA Price Performance

XOMA stock opened at $24.78 on Wednesday. The company has a market capitalization of $288.44 million, a PE ratio of -6.13 and a beta of 0.57. The business has a 50 day simple moving average of $25.13 and a 200 day simple moving average of $20.77. XOMA has a one year low of $13.48 and a one year high of $27.00. The company has a debt-to-equity ratio of 1.34, a current ratio of 8.68 and a quick ratio of 8.68.

XOMA (NASDAQ:XOMA) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. On average, sell-side analysts forecast that XOMA will post -2.11 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC boosted its position in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the quarter. XOMA accounts for approximately 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 12th biggest holding. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.